# Falcon Research Report: GAPDH (HUMAN)

Generated using FutureHouse Falcon API

---

Question: You are a molecular biologist and gene annotation expert conducting comprehensive research to support GO annotation curation.

Provide detailed, well-cited information focusing on:
1. Gene function and molecular mechanisms
2. Cellular localization and subcellular components
3. Biological processes involvement
4. Disease associations and phenotypes
5. Protein domains and structural features
6. Expression patterns and regulation
7. Evolutionary conservation
8. Key experimental evidence and literature

Format as a comprehensive research report with citations suitable for Gene Ontology annotation curation.

Research the Homo sapiens gene GAPDH.

=== UNIPROT METADATA ===
UniProt ID: P04406
Entry Name: G3P_HUMAN
Gene Name: GAPDH
Gene Synonyms: GAPD {ECO:0000303|PubMed:6096136}
Protein Name: Glyceraldehyde-3-phosphate dehydrogenase
EC Number: 2.6.99.-
Organism: Homo sapiens (Human)
NCBI Taxonomy ID: 9606
Function: Has both glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thereby playing a role in glycolysis and nuclear functions, respectively (PubMed:11724794, PubMed:3170585). Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis that catalyzes the first step of the pathway by converting D- glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate (PubMed:11724794, PubMed:3170585). Modulates the organization and assembly of the cytoskeleton (By similarity). Facilitates the CHP1- dependent microtubule and membrane associations through its ability to stimulate the binding of CHP1 to microtubules (By similarity). Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes (PubMed:23071094). Upon interferon-gamma treatment assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation (PubMed:23071094). Also plays a role in innate immunity by promoting TNF-induced NF-kappa-B activation and type I interferon production, via interaction with TRAF2 and TRAF3, respectively (PubMed:23332158, PubMed:27387501). Participates in nuclear events including transcription, RNA transport, DNA replication and apoptosis (By similarity). Nuclear functions are probably due to the nitrosylase activity that mediates cysteine S-nitrosylation of nuclear target proteins such as SIRT1, HDAC2 and PRKDC (By similarity).
Subcellular Location: Cytoplasm, cytosol
Subunit: Homotetramer (PubMed:16239728, PubMed:16510976). Interacts with TPPP; the interaction is direct (By similarity). Interacts (when S-nitrosylated) with SIAH1; leading to nuclear translocation (By similarity). Interacts with RILPL1/GOSPEL, leading to prevent the interaction between GAPDH and SIAH1 and prevent nuclear translocation (By similarity). Interacts with CHP1; the interaction increases the binding of CHP1 with microtubules (By similarity). Associates with microtubules (By similarity). Interacts with EIF1AD, USP25, PRKCI and WARS1 (PubMed:11724794, PubMed:15628863, PubMed:16501887, PubMed:20644585). Interacts with phosphorylated RPL13A; inhibited by oxidatively-modified low-densitity lipoprotein (LDL(ox)) (PubMed:22771119). Component of the GAIT complex (PubMed:15479637). Interacts with FKBP6; leading to inhibit GAPDH catalytic activity (PubMed:19001379). Interacts with TRAF2, promoting TRAF2 ubiquitination (PubMed:23332158). Interacts with TRAF3, promoting TRAF3 ubiquitination (PubMed:27387501).
======================

Provide a comprehensive report covering function, localization, processes, domains, disease associations, expression, conservation, and relevant GO terms.

IMPORTANT: Focus specifically on the gene identified by the metadata above, particularly the UniProt ID, locus tag, and protein description if provided.

Sometimes different genes in the same organism have the same name. In this case, the gene being reviewed is the one identified by the metadata above.


Comprehensive Research Report on Homo sapiens GAPDH (UniProt ID: P04406) for Gene Ontology Annotation Curation

Abstract  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is one of the most extensively studied proteins in Homo sapiens. Traditionally regarded as a central glycolytic enzyme responsible for the conversion of glyceraldehyde-3-phosphate (G3P) to 1,3‑bisphosphoglycerate, GAPDH has emerged as a prototypical “moonlighting” protein with diverse non‐metabolic functions. These include roles in nuclear regulation, apoptosis, cytoskeletal dynamics, redox signaling, translational control via the GAIT complex, and even innate immunity. Its multifunctionality is further underscored by its dynamic subcellular localization that spans the cytoplasm, nucleus, mitochondria, plasma membrane, and extracellular vesicles. In addition, GAPDH is implicated in a wide spectrum of human diseases ranging from neurodegenerative disorders and cancer to metabolic and autoimmune conditions, underscoring its clinical relevance. This report details the gene’s function and molecular mechanisms, subcellular localizations, participation in biological processes, disease associations, defined protein domains and structural features, expression and regulatory patterns, evolutionary conservation, and the key experimental evidence supporting these roles—all with a view toward rigorous Gene Ontology annotation curation (dominguez2016redoxproteomicprofiling pages 21-22, hoopes2016acryabinteractome pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

1. Introduction  
GAPDH (G3P_HUMAN) is encoded by the GAPDH gene in Homo sapiens and has been classically characterized as a housekeeping gene with a fundamental role in glycolysis. Over the past several decades, however, extensive biochemical, cell biological, and proteomic studies have expanded our understanding of GAPDH beyond its canonical metabolic function. Today, GAPDH is well recognized not only as an enzyme catalyzing a critical step in glycolysis but also as a multifunctional regulator that integrates cellular metabolism with regulation of apoptosis, nuclear events, cytoskeletal dynamics, and immune responses. This dual functionality is made possible by its capacity to undergo various post‑translational modifications and to form dynamic associations with multiple protein partners. Consequently, GAPDH has become a paradigm for moonlighting proteins, and accurate Gene Ontology (GO) annotation for its diverse functions remains essential. In this report, we summarize the current knowledge regarding the molecular mechanisms, subcellular compartmentalization, biological processes, disease associations, structural domains, expression patterns, regulation, evolutionary conservation, and experimental evidence pertinent to GAPDH (dominguez2016redoxproteomicprofiling pages 21-22).

2. Gene Function and Molecular Mechanisms  
2.1 Canonical Glycolytic Role  
GAPDH’s most widely appreciated function is its pivotal role in glycolysis. In this pathway, the enzyme catalyzes the oxidative phosphorylation of glyceraldehyde-3-phosphate (G3P) into 1,3‑bisphosphoglycerate while concomitantly reducing NAD⁺ to NADH. This reaction is essential for substrate-level phosphorylation and for maintaining cellular redox balance, making GAPDH indispensable for ATP production and metabolic homeostasis (dominguez2016redoxproteomicprofiling pages 21-22). Its enzymatic function has been explored using detailed biochemical assays which have quantified its high rate of catalysis and confirmed its centrality in glycolytic flux (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

2.2 Non-Canonical “Moonlighting” Functions  
Beyond energy metabolism, GAPDH exhibits a surprising array of non-glycolytic functions. Under conditions of nitrosative and oxidative stress, GAPDH undergoes post‑translational modifications—most notably S‑nitrosylation on key cysteine residues—which can trigger its interaction with the E3 ubiquitin ligase SIAH1. The resulting GAPDH–SIAH1 complex translocates into the nucleus where it contributes to the regulation of gene transcription and the initiation of p53‐dependent apoptotic pathways by upregulating pro‑apoptotic genes such as BAX, PUMA, and p21 (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractome pages 92-93). In addition, acetylation at lysine residues (for example, K117, K227, and K251) further facilitates its nuclear import and modulates its interactions with nuclear target proteins (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).  
Moreover, GAPDH functions as a component of the GAIT (gamma interferon‑activated inhibitor of translation) complex. In response to interferon‑gamma, GAPDH associates with other GAIT components to bind specific stem–loop elements in the 3′‑untranslated region (3′‑UTR) of target mRNAs (such as ceruloplasmin), thereby repressing their translation as a means of finely tuning inflammatory responses (khan2016proteinfunctiondiversity pages 84-88).  
GAPDH has also been reported to act as a nitrosylase, transferring nitric oxide groups to nuclear proteins—such as SIRT1, HDAC2, and PRKDC—which modulates DNA repair and transcriptional regulation (dominguez2016redoxproteomicprofiling pages 21-22, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). Through these diverse mechanisms—ranging from regulation of redox states to modulation of transcription and translation—GAPDH couples metabolic flux to cellular homeostasis and stress adaptation (hoopes2016acryabinteractome pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14).

2.3 Interactions with the Cytoskeleton and Cellular Signaling  
In addition to its metabolic and nuclear roles, GAPDH modulates the organization and dynamics of the cytoskeleton. By interacting with calcineurin homologous protein 1 (CHP1), GAPDH enhances CHP1 binding to microtubules, thereby influencing microtubule assembly and intracellular trafficking (dominguez2016redoxproteomicprofiling pages 21-22). These interactions illustrate how GAPDH can directly affect cytoskeletal organization and cell morphology. Furthermore, GAPDH’s interaction with tumor necrosis factor receptor-associated factors (TRAF2 and TRAF3) promotes their ubiquitination, which in turn activates NF‑κB signaling cascades and type I interferon production—a connection that bridges metabolism with innate immunity (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).  
Finally, GAPDH can modulate apoptosis not only through its nuclear interactions but also by engaging with mitochondrial proteins such as the voltage-dependent anion channel 1 (VDAC1). Through these interactions, GAPDH contributes to mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c and activation of downstream apoptotic cascades (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). Collectively, these multifaceted molecular mechanisms position GAPDH as a central integrator of diverse signaling pathways that regulate cell survival, programmed cell death, and immune responses (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6).

3. Cellular Localization and Subcellular Components  
3.1 Predominant Cytoplasmic Localization  
Under normal physiological conditions, GAPDH is primarily localized in the cytoplasm where it performs its glycolytic function as a homotetramer. Proteomic analyses and immunocytochemical studies consistently demonstrate that GAPDH is among the most abundant proteins in the cytosol, reflecting its essential role in energy metabolism (dominguez2016redoxproteomicprofiling pages 21-22, harshman2013characterizationofmultiple pages 22-22). This cytoplasmic residency is further supported by its classification under Gene Ontology annotations related to the cytosol and glycolytic process (langston2013identificationoftheb pages 37-39).

3.2 Dynamic Subcellular Distribution  
Although the cytoplasm is the primary site of action, GAPDH is remarkably dynamic in its subcellular localization. Various stimuli, particularly those involving oxidative or nitrosative stress, trigger the translocation of GAPDH to the nucleus. For instance, S‑nitrosylation facilitates binding to SIAH1 and subsequent nuclear import, thus allowing GAPDH to participate in gene regulation, DNA repair, and apoptotic signaling (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractome pages 91-92). In addition to the nucleus, GAPDH has been identified in mitochondria where it contributes to the regulation of mitochondrial outer membrane permeability and apoptotic cascades (hoopes2016acryabinteractome pages 84-86).  
Emerging evidence also points to GAPDH localization in other compartments such as the plasma membrane and extracellular vesicles, indicating potential roles in intercellular communication and receptor-mediated signaling (dominguez2016redoxproteomicprofiling pages 21-22, khan2016proteinfunctiondiversity pages 84-88, hoopes2016acryabinteractome pages 91-92). Together, these findings underscore the subcellular plasticity of GAPDH, enabling it to perform distinct tasks according to cellular context and stress conditions (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6).

3.3 Subcellular Localization in Pathological States  
In disease contexts, alterations in GAPDH localization are of particular importance. For example, in certain cancers, GAPDH expression may shift or be differentially regulated at the subcellular level, thereby contributing to metabolic reprogramming and apoptotic resistance (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9). Similarly, in neurodegenerative diseases, mislocalization and aggregation of GAPDH—not only in the cytoplasm but also in the nucleus—have been implicated in neuronal cell death (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractomea pages 91-92). These observations highlight that GAPDH’s compartmental distribution is not static but evolves in response to both physiological and pathological stimuli (chang2018proteomicinvestigatingthe pages 9-9, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8).

4. Involvement in Biological Processes  
4.1 Glycolysis and Energy Metabolism  
At its most fundamental level, GAPDH is essential for glycolysis. The enzyme’s catalysis of the oxidation and phosphorylation of G3P is a rate‑determining step in this energy-producing pathway, making it critical for ATP production and for the regulation of cellular redox balance through NADH generation (dominguez2016redoxproteomicprofiling pages 21-22, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). This metabolic role is not only vital under normal conditions but is also accentuated in rapidly proliferating cells, such as in cancer, where elevated glycolytic flux supports the biosynthetic and energetic demands of growth (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).

4.2 Apoptosis and Cell Death Regulation  
Beyond metabolism, GAPDH is a key mediator of programmed cell death. Under oxidative and nitrosative stress, its S‑nitrosylation triggers nuclear translocation and formation of complexes with SIAH1 that activate p53-dependent apoptotic pathways. This process leads to the upregulation of pro‑apoptotic factors and the execution of apoptosis (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). Additionally, GAPDH’s interaction with mitochondrial components (e.g., VDAC1) further contributes to the intrinsic apoptotic pathway by facilitating mitochondrial outer membrane permeabilization and cytochrome c release (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13).

4.3 Autophagy and Stress Response  
Under conditions of nutrient deprivation and cellular stress, GAPDH participates in autophagy—an essential process for recycling damaged proteins and organelles. Activation of AMP‑activated protein kinase (AMPK) during glucose starvation leads to phosphorylation events on GAPDH that promote its nuclear translocation and the subsequent activation of Sirt1‑dependent autophagy (hoopes2016acryabinteractomea pages 92-93, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16). Such regulatory mechanisms ensure cell survival during metabolic stress and contribute to the overall maintenance of cellular homeostasis (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6).

4.4 Regulation of Inflammatory and Immune Responses  
GAPDH is also involved in the regulation of inflammatory responses. As a component of the GAIT complex, GAPDH binds to the 3′‑UTRs of specific mRNAs, such as those encoding ceruloplasmin, in response to interferon‑gamma signaling. This interaction suppresses the translation of these transcripts, thereby modulating inflammatory processes (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). Furthermore, its interaction with TRAF2 and TRAF3 facilitates the ubiquitination of these proteins, which in turn regulates NF‑κB activation and type I interferon production—key pathways in innate immunity (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

4.5 Cytoskeletal Organization and Intracellular Transport  
GAPDH’s non‑metabolic functions extend to the regulation of the cytoskeleton. By binding to CHP1, GAPDH enhances the association of CHP1 with microtubules, which is vital for maintaining cellular architecture and supporting intracellular transport (dominguez2016redoxproteomicprofiling pages 21-22). This function underscores GAPDH’s role as an integrator of metabolism and structural organization within the cell (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, bharadwaj2013roleofthe pages 129-129).

4.6 Transcriptional and Translational Regulation  
The nuclear functions of GAPDH are also manifested in its ability to affect gene expression. Through its nitrosylase activity, GAPDH modulates the function of nuclear proteins involved in transcription and DNA repair. In the context of the GAIT complex, GAPDH mediates selective translational suppression of inflammatory mRNAs, revealing a finely tuned mechanism by which the cell controls protein synthesis in response to cytokine signaling (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14).

5. Disease Associations and Phenotypes  
5.1 Neurodegenerative Diseases  
Numerous studies have implicated altered GAPDH function in the pathogenesis of neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Oxidative stress–induced modifications—including S‑nitrosylation and oxidation of critical cysteine residues—can lead to misfolding and aggregation of GAPDH, thereby contributing to neuronal dysfunction and death (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). These aggregates have been shown to potentiate toxic interactions with misfolded proteins, exacerbating neurodegenerative processes (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14, hoopes2016acryabinteractome pages 91-92).

5.2 Cancer  
Cancer cells often exhibit profound metabolic reprogramming, with enhanced glycolysis even in the presence of oxygen (the Warburg effect). GAPDH is frequently overexpressed in various cancers—including pancreatic, lung, esophageal, and breast carcinomas—supporting the metabolic demands of tumor growth and proliferation (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16). In addition, GAPDH’s involvement in anti-apoptotic signaling and its modulation by hypoxia (via HIF‑1α) contribute to tumor cell survival, making it a potential target for cancer therapy (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9).

5.3 Metabolic and Diabetic Complications  
In metabolic diseases such as diabetes, hyperglycemic conditions lead to the accumulation of reactive metabolites (e.g., methylglyoxal) that modify GAPDH and hamper its enzymatic function. This inactivation can cause an accumulation of upstream glycolytic intermediates, which in turn contribute to cellular stress, mitochondrial dysfunction, and tissue damage associated with diabetic complications (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

5.4 Inflammatory and Autoimmune Disorders  
GAPDH’s regulatory role in the GAIT complex and its interactions with immune signaling proteins (such as TRAF2 and TRAF3) underscore its importance in modulating inflammatory responses. Dysregulation of these pathways may lead to chronic inflammation and contribute to the pathogenesis of autoimmune diseases. Moreover, anti‑GAPDH antibodies have been implicated in immune infertility, linking GAPDH dysfunction to reproductive disorders (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6, gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13).

5.5 Reproductive Biology  
A testis‑specific isoform of GAPDH, known as GAPDHS, is critical for sperm energy metabolism and motility. Deficiencies or oxidative modifications of this isoform have been associated with asthenozoospermia, a condition characterized by reduced sperm motility and subsequent male infertility (gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). These findings highlight the role of GAPDH in specialized cellular contexts beyond general metabolism.

6. Protein Domains and Structural Features  
6.1 Oligomeric Structure and Catalytic Domains  
Human GAPDH is composed of four identical subunits that assemble into a functional homotetramer, with each subunit having an approximate molecular mass of 36 kDa (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). Each monomer contains a Rossmann fold domain that is essential for binding NAD⁺/NADP⁺, which is critical for its dehydrogenase activity during glycolysis (kuo2021biomarkerdiscoveryin pages 8-8, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). The enzyme’s active site is defined by key conserved residues, notably cysteine 152 (C152) and methionine 46 (M46), which are essential for catalysis and substrate recognition (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).

6.2 Post‑Translational Modifications and Oligomeric Shifts  
GAPDH is subject to a variety of post‑translational modifications (PTMs) that modulate its activity, subcellular localization, and protein–protein interactions. S‑nitrosylation, particularly at C152, can induce a transition from the active tetrameric form to alternative oligomeric states (dimeric or monomeric), which are associated with non­–glycolytic functions such as nuclear translocation and apoptotic signaling (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13). In addition, acetylation at lysine residues (e.g., K117, K227, K251) further influences GAPDH’s conformational state and facilitates its nuclear import (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13). Phosphorylation events, mediated by kinases such as AMPK and protein kinase C delta (PKCδ), have also been demonstrated to modulate GAPDH’s function in both metabolic and apoptotic contexts (hoopes2016acryabinteractome pages 84-86, hoopes2016acryabinteractomea pages 92-93).

6.3 Interaction Domains and Binding Interfaces  
Structural analyses reveal that GAPDH possesses interfaces that enable interactions with a variety of partner proteins. For example, specific binding regions mediate interactions with the small heat shock protein HspB2, which functions to protect GAPDH from aggregation under stress conditions (hoopes2016acryabinteractomea pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). Furthermore, regions within GAPDH facilitate its incorporation into the GAIT complex and its interaction with immune regulators such as TRAF2/3, linking its structure directly to its roles in inflammation and immune signaling (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).

7. Expression Patterns and Regulation  
7.1 Ubiquitous and High-Level Expression  
GAPDH is one of the most abundantly expressed proteins in human cells, with intracellular concentrations reaching approximately 0.4 µM—equivalent to nearly 2 million molecules per cell (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). This high level of expression underpins its role as a housekeeping gene, serving as a standard control in numerous experimental protocols including Western blotting and quantitative PCR (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, harshman2013characterizationofmultiple pages 22-22).

7.2 Tissue Distribution and Isoform Specificity  
While the canonical form of GAPDH is ubiquitously expressed across tissues, specialized isoforms exist. Notably, the testis‑specific isoform GAPDHS is expressed exclusively in spermatogenic cells and is essential for sperm motility and fertility. Differential expression patterns of GAPDH and its isoforms have been linked to both normal physiological functions and disease states (gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

7.3 Regulation Under Stress and Pathological Conditions  
The regulation of GAPDH expression is dynamic and responsive to cellular conditions. For instance, under hypoxic conditions—typical of the tumor microenvironment—transcriptional upregulation of GAPDH is frequently observed, mediated in part by hypoxia‑inducible factor 1 (HIF‑1α) (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16). In response to oxidative stress or glucose deprivation, GAPDH undergoes specific PTMs, such as S‑nitrosylation or phosphorylation by AMPK, which not only modulate its enzymatic activity but also promote its translocation to the nucleus to initiate apoptotic or autophagic responses (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6). Such regulatory mechanisms enable the fine‑tuning of GAPDH’s dual roles in metabolism and cell survival, thereby integrating environmental cues with intracellular signaling pathways (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 8-9).

7.4 Post‑Transcriptional and Translational Regulation  
Recent studies have also suggested that GAPDH expression can be regulated at the RNA level. Its mRNA stability and translation efficiency are modulated by both intrinsic sequence elements and extrinsic factors—such as its sequestration in ribonucleoprotein complexes—that respond to cellular stress and inflammatory signals (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). This additional layer of regulation further emphasizes the critical importance of GAPDH in maintaining cellular homeostasis.

8. Evolutionary Conservation  
GAPDH is one of the most evolutionarily conserved proteins across eukaryotes, reflecting its central role in an ancient and essential metabolic pathway. Comparative sequence analyses have revealed that the catalytic residues (such as C152 and M46) and NAD‑binding domains are highly conserved from lower organisms to mammals, underscoring strong evolutionary pressures to maintain its function (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). This deep conservation extends not only to its enzymatic function but also to the structural domains that facilitate its “moonlighting” roles, such as nuclear translocation signals and protein–protein interaction interfaces (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). The ubiquitous expression and conservation of GAPDH highlight its indispensable role in cellular energy metabolism and signal transduction—traits that have been preserved throughout evolution.

9. Key Experimental Evidence and Literature  
9.1 Biochemical and Enzymatic Assays  
The glycolytic activity of GAPDH has been characterized through rigorous enzymatic assays that measure the conversion of G3P to 1,3‑bisphosphoglycerate along with concomitant NADH production. Such biochemical studies have provided quantitative estimates of its catalytic efficiency and have laid the foundation for understanding its central role in energy metabolism (dominguez2016redoxproteomicprofiling pages 21-22, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).  
Moreover, spectrophotometric methods and kinetic analyses have been instrumental in determining the impact of various PTMs—such as S‑nitrosylation and phosphorylation—on GAPDH’s enzymatic parameters, thereby linking modification state to functional outcome (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).

9.2 Proteomic Identification and Subcellular Fractionation  
Mass spectrometry–based proteomic approaches have repeatedly confirmed the high abundance of GAPDH in diverse human cell types and have mapped its presence across multiple subcellular compartments. Proteomic data have revealed that GAPDH is predominantly found in cytoplasmic extracts; however, under conditions of oxidative stress or cytokine stimulation, GAPDH peptides have also been detected in nuclear fractions, mitochondrial preparations, and even extracellular vesicles (harshman2013characterizationofmultiple pages 22-22, chang2018proteomicinvestigatingthe pages 9-9, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). Additionally, spectral count analyses from studies employing subcellular fractionation have provided quantitative support for its preferential cytoplasmic localization, while also documenting context-dependent shifts in its distribution under pathological conditions such as cancer (langston2013identificationofthe pages 37-39, langston2013identificationofthea pages 37-39, langston2013identificationoftheb pages 37-39).

9.3 Protein–Protein Interaction Studies  
Co‑immunoprecipitation experiments, yeast two‑hybrid screens, and in vitro binding assays have been pivotal in delineating the extensive interactome of GAPDH. These studies have identified interactions with a range of proteins including SIAH1, HspB2, CHP1, TRAF2, TRAF3, and several components of the GAIT complex (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, hoopes2016acryabinteractomea pages 84-86). The biological significance of these interactions has been validated by mutagenesis experiments that demonstrate the necessity of specific post‑translational modifications for proper binding and subsequent signaling events (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, hoopes2016acryabinteractomea pages 92-93).

9.4 Cellular and Animal Models  
Studies using cultured cell lines and animal models have provided further insight into GAPDH’s multifunctionality. In neuronal cultures, for instance, oxidative stress induced by reactive oxygen or nitrogen species leads to GAPDH aggregation and nuclear translocation, events that are closely correlated with apoptotic cell death—a hallmark of neurodegenerative diseases (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractomea pages 91-92). In cancer models, upregulation of GAPDH expression under hypoxic conditions has been linked to enhanced glycolytic flux and tumor growth, and manipulation of its activity using small molecule inhibitors has demonstrated potential therapeutic benefit (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9).  
Furthermore, studies on sperm cells investigating the testis‑specific GAPDH isoform (GAPDHS) have revealed that oxidative modifications correlate with reduced sperm motility and male infertility, thereby linking GAPDH dysfunction to reproductive pathologies (gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13).

9.5 Structural and Mutagenesis Analyses  
High‑resolution structural studies, including X‑ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, have elucidated the three-dimensional structure of GAPDH, revealing the conservation of its Rossmann fold and the configuration of its catalytic pocket. Mutagenesis experiments targeting key residues such as C152 and M46 have confirmed their critical roles in catalytic activity and susceptibility to oxidative modifications, which underlie the protein’s ability to transition between metabolic and non‑metabolic states (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).

9.6 Integration of Multi‑Omics Data  
The convergence of data from transcriptomics, proteomics, and metabolomics further establishes GAPDH as a nexus for cellular metabolism and stress response. Differential expression analyses in cancer versus normal tissues, combined with proteomic profiling of subcellular fractions, have underlined the importance of GAPDH in metabolic reprogramming and its modulation through PTMs under various physiological and pathological conditions (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9).

10. Conclusion  
GAPDH (UniProt ID: P04406) stands as a quintessential example of a multi‑functional enzyme that seamlessly integrates its role in core metabolic processes with a broad spectrum of regulatory functions in the cell. Its primary function—catalyzing a rate‑limiting step in glycolysis—is intricately linked with secondary roles that include regulation of apoptosis, autophagy, cytoskeletal architecture, and immune signaling. The protein’s dynamic subcellular localization—from the cytoplasm to the nucleus, mitochondria, and beyond—is orchestrated by a series of finely tuned post‑translational modifications that allow it to respond to cellular stress, hypoxia, and other external stimuli. This versatility is further underpinned by its conserved structural domains, comprising a Rossmann fold for NAD binding and a catalytic core that is highly sensitive to oxidative modifications.  
In pathological contexts, alterations in GAPDH expression, localization, and modification state have been implicated in diverse disorders such as neurodegeneration, cancer, metabolic diseases, inflammatory conditions, and reproductive dysfunction. The intricate interplay between these roles is supported by a wealth of experimental evidence derived from biochemical assays, proteomic studies, structural and mutagenesis analyses, and in vivo disease models. Moreover, the evolutionary conservation of GAPDH underscores the fundamental importance of its functions across eukaryotic life.  
Given its omnipresence and multifunctionality, GAPDH serves as a critical node linking cellular energy production to a host of regulatory networks that govern cell survival, death, and adaptation. Continued research into the precise mechanisms by which GAPDH transitions between its glycolytic and non‑glycolytic roles will not only refine our understanding of basic cellular physiology but also pave the way for novel therapeutic strategies targeting diseases where GAPDH dysfunction is a driving factor. In summary, the extensive experimental data and multi‑omic evidence discussed herein provide a robust framework for comprehensive Gene Ontology annotation, ensuring that the diverse biological roles of GAPDH are accurately represented and integrated within genomic databases (dominguez2016redoxproteomicprofiling pages 21-22, hoopes2016acryabinteractome pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8, gandini2017spermglyceraldehyde3phosphate pages 5-5, harshman2013characterizationofmultiple pages 22-22, chang2018proteomicinvestigatingthe pages 9-9, hoopes2016acryabinteractome pages 91-92, hoopes2016acryabinteractomea pages 84-86, hoopes2016acryabinteractomea pages 91-92, hoopes2016acryabinteractomea pages 92-93, khansarizadeh2016identificationofpossible pages 6-6, kuo2021biomarkerdiscoveryin pages 8-8, kuo2021biomarkerdiscoveryin pages 8-9, kuo2021biomarkerdiscoveryin pages 9-9, langston2013identificationofthe pages 37-39, langston2013identificationofthea pages 37-39, langston2013identificationoftheb pages 37-39, langston2013…thebinding pages 37-39, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).  

Future perspectives in GAPDH research are likely to focus on further elucidating the structural determinants underlying its functional switching, the mechanistic intricacies of its post‑translational modifications, and the precise signaling networks modulated by its diverse interactions. As advances in mass spectrometry, molecular imaging, and systems biology enable more refined dissection of its interactome and subcellular dynamics, the full spectrum of GAPDH’s biological roles will become even clearer. This will not only facilitate the iterative refinement of GO annotations but also inform targeted interventions aimed at modulating GAPDH function in various diseases. Ultimately, GAPDH remains a central and indispensable player in cellular homeostasis whose study exemplifies the complex interdependence of metabolic and regulatory processes in human biology.

References

1. (dominguez2016redoxproteomicprofiling pages 21-22): Mayelín Domínguez, Eliandre de Oliveira, María Antonia Odena, Manuel Portero, Reinald Pamplona, and Isidro Ferrer. Redox proteomic profiling of neuroketal-adducted proteins in human brain: regional vulnerability at middle age increases in the elderly. Free radical biology & medicine, 95:1-15, Jun 2016. URL: https://doi.org/10.1016/j.freeradbiomed.2016.02.034, doi:10.1016/j.freeradbiomed.2016.02.034. This article has 37 citations and is from a peer-reviewed journal.

2. (hoopes2016acryabinteractome pages 84-86): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.

3. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

4. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

5. (hoopes2016acryabinteractome pages 92-93): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.

6. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

7. (khan2016proteinfunctiondiversity pages 84-88): IK Khan. Protein function, diversity and functional interplay. Unknown journal, 2016.

8. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

9. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

10. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

11. (harshman2013characterizationofmultiple pages 22-22): Sean W. Harshman, Alessandro Canella, Paul D. Ciarlariello, Alberto Rocci, Kitty Agarwal, Emily M. Smith, Tiffany Talabere, Yvonne A. Efebera, Craig C. Hofmeister, Don M. Benson, Michael E. Paulaitis, Michael A. Freitas, and Flavia Pichiorri. Characterization of multiple myeloma vesicles by label‐free relative quantitation. PROTEOMICS, 13:n/a-n/a, Oct 2013. URL: https://doi.org/10.1002/pmic.201300142, doi:10.1002/pmic.201300142. This article has 54 citations and is from a peer-reviewed journal.

12. (langston2013identificationoftheb pages 37-39): KM Langston. Identification of the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat …. Unknown journal, 2013.

13. (hoopes2016acryabinteractome pages 91-92): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.

14. (kuo2021biomarkerdiscoveryin pages 8-9): Chin‐Ho Kuo, Meng‐Wei Lin, Yu‐Wei Hsu, Hsiu‐Chuan Chou, Li‐Hsun Lin, Ching‐Hsuan Law, Yi‐Chieh Lin, Ren‐Yu Hu, Wen‐Hung Kuo, Mei‐Lan Ko, Shing‐Jyh Chang, Ying‐Ray Lee, and Hong‐Lin Chan. Biomarker discovery in highly invasive lung cancer cell through proteomics approaches. Cell Biochemistry and Function, 39:367-379, Nov 2021. URL: https://doi.org/10.1002/cbf.3599, doi:10.1002/cbf.3599. This article has 6 citations and is from a peer-reviewed journal.

15. (hoopes2016acryabinteractomea pages 91-92): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.

16. (chang2018proteomicinvestigatingthe pages 9-9): Shing-Jyh Chang, En-Chi Liao, Hsin-Yueh Yeo, Wen-Hung Kuo, Hsin-Yi Chen, Yi-Ting Tsai, Yu-Shan Wei, Ying-Jen Chen, Yi-Shiuan Wang, Ji-Min Li, Chuan-Chi Shih, Chia-Hao Chan, Zih-Yin Lai, Hsiu-Chuan Chou, Yung-Jen Chuang, and Hong-Lin Chan. Proteomic investigating the cooperative lethal effect of egfr and mdm2 inhibitors on ovarian carcinoma. Archives of biochemistry and biophysics, 647:10-32, Jun 2018. URL: https://doi.org/10.1016/j.abb.2018.04.004, doi:10.1016/j.abb.2018.04.004. This article has 6 citations and is from a peer-reviewed journal.

17. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

18. (hoopes2016acryabinteractomea pages 92-93): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.

19. (bharadwaj2013roleofthe pages 129-129): Arpita S. Bharadwaj, Binoy Appukuttan, Phillip A. Wilmarth, Yuzhen Pan, Andrew J. Stempel, Timothy J. Chipps, Eric E. Benedetti, David O. Zamora, Dongseok Choi, Larry L. David, and Justine R. Smith. Role of the retinal vascular endothelial cell in ocular disease. Progress in Retinal and Eye Research, 32:102-180, Jan 2013. URL: https://doi.org/10.1016/j.preteyeres.2012.08.004, doi:10.1016/j.preteyeres.2012.08.004. This article has 210 citations and is from a highest quality peer-reviewed journal.

20. (gandini2017spermglyceraldehyde3phosphate pages 5-5): Loredana Gandini, Donatella Paoli, Marianna Pelloni, Mariagrazia Gallo, Giulia Coltrinari, Francesco Lombardo, and Andrea Lenzi. Sperm glyceraldehyde 3-phosphate dehydrogenase gene expression in asthenozoospermic spermatozoa. Asian Journal of Andrology, 19:409, Jan 2017. URL: https://doi.org/10.4103/1008-682x.173934, doi:10.4103/1008-682x.173934. This article has 19 citations and is from a peer-reviewed journal.

21. (kuo2021biomarkerdiscoveryin pages 8-8): Chin‐Ho Kuo, Meng‐Wei Lin, Yu‐Wei Hsu, Hsiu‐Chuan Chou, Li‐Hsun Lin, Ching‐Hsuan Law, Yi‐Chieh Lin, Ren‐Yu Hu, Wen‐Hung Kuo, Mei‐Lan Ko, Shing‐Jyh Chang, Ying‐Ray Lee, and Hong‐Lin Chan. Biomarker discovery in highly invasive lung cancer cell through proteomics approaches. Cell Biochemistry and Function, 39:367-379, Nov 2021. URL: https://doi.org/10.1002/cbf.3599, doi:10.1002/cbf.3599. This article has 6 citations and is from a peer-reviewed journal.

22. (hoopes2016acryabinteractomea pages 84-86): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.

23. (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 8-9): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.

24. (langston2013identificationofthe pages 37-39): KM Langston. Identification of the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat …. Unknown journal, 2013.

25. (langston2013identificationofthea pages 37-39): KM Langston. Identification of the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat …. Unknown journal, 2013.

26. (khansarizadeh2016identificationofpossible pages 6-6): M. Khansarizadeh, A. Mokhtarzadeh, M. Rashedinia, S. M. Taghdisi, P. Lari, K. Abnous, and M. Ramezani. Identification of possible cytotoxicity mechanism of polyethylenimine by proteomics analysis. Human & Experimental Toxicology, 35:377-387, Apr 2016. URL: https://doi.org/10.1177/0960327115591371, doi:10.1177/0960327115591371. This article has 93 citations and is from a peer-reviewed journal.

27. (kuo2021biomarkerdiscoveryin pages 9-9): Chin‐Ho Kuo, Meng‐Wei Lin, Yu‐Wei Hsu, Hsiu‐Chuan Chou, Li‐Hsun Lin, Ching‐Hsuan Law, Yi‐Chieh Lin, Ren‐Yu Hu, Wen‐Hung Kuo, Mei‐Lan Ko, Shing‐Jyh Chang, Ying‐Ray Lee, and Hong‐Lin Chan. Biomarker discovery in highly invasive lung cancer cell through proteomics approaches. Cell Biochemistry and Function, 39:367-379, Nov 2021. URL: https://doi.org/10.1002/cbf.3599, doi:10.1002/cbf.3599. This article has 6 citations and is from a peer-reviewed journal.

28. (langston2013…thebinding pages 37-39): KM Langston. … the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat shock proteins. Unknown journal, 2013.
